Adhesion of renal carcinoma cells to endothelial cells depends on PKCmu.
BACKGROUND
The formation of metastases includes the separation of tumor cells from the primary tumor, cell migration into subendothelial tissue and cell proliferation in secondary organ. In this process, cell adhesion of tumor cells to the endothelium is an essential requirement for formation of metastases. Protein kinase C (PKC) regulates adhesion and proliferation. To identify a relation between PKC isoforms and tumor progression in renal cell carcinoma (RCC), the influence of PKC isoforms on cell adhesion and proliferation, and possible influences of integrins were analyzed in RCC cells.


METHODS
The experiments were performed in the RCC cell lines CCF-RC1 and CCF-RC2 after pre-incubation (16 h) with the PKC inhibitors GF109203X (inhibits PKCalpha, betaI, betaII, gamma, delta and epsilon), GO6976 (inhibits PKCalpha, betaI and mu), RO31-8220 (inhibits PKCalpha, betaI, betaII, gamma and epsilon) and rottlerin (inhibits PKCdelta). Cell adhesion was assessed through adherence of RCC cells to an endothelial monolayer. Cell proliferation was analyzed by a BrdU incorporation assay. The expression of beta1 integrins was analyzed by flow cytometry.


RESULTS
In CCF-RC1 cells, cell adhesion was significantly reduced by GO6976 to 55% and by RO31-8220 to 45% of control. In CCF-RC2 cells, only GO6976 induced a significant reduction of cell adhesion to 50% of control levels. Proliferation of both cell lines was reduced by rottlerin to 39% and 45% of control, respectively. The beta1 integrin expression on the cell surface of CCF-RC1 and CCR-RC2 cells was decreased by RO31-8220 to 8% and 7% of control, respectively. beta2 and beta3 integrins were undetectable in both cell lines.


CONCLUSIONS
The combination of the PKC inhibitors leads to the assumption that PKCmu influences cell adhesion in CCF-RC1 and CCF-RC2 cells, whereas in CCF-RC1 cells PKCepsilon also seems to be involved in this process. The expression of beta1 integrins appears to be regulated in particular by PKCepsilon. Cell proliferation was inhibited by rottlerin, so that PKCdelta might be involved in cell proliferation in these cells.
Brenner
Walburgis
W
Department of Urology, University Medical Center Mainz, Mainz, Germany. brenner@uni-mainz.de
Beitz
Silke
S
Schneider
Elke
E
Benzing
Frank
F
Unger
Ronald E
RE
Roos
Frederik C
FC
Thüroff
Joachim W
JW
Hampel
Christian
C
D002292:Carcinoma, Renal Cell / Q000201:enzymology* / Q000473:pathology*; D002448:Cell Adhesion / Q000502:physiology; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D042783:Endothelial Cells / Q000166:cytology; D006801:Humans; D039641:Integrin beta Chains / Q000096:biosynthesis; D007680:Kidney Neoplasms / Q000201:enzymology* / Q000473:pathology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology
D039641:Integrin beta Chains; D047428:Protein Kinase Inhibitors; C089212:protein kinase D; D011493:Protein Kinase C
J Urol. 1996 Feb;155(2):743-8
8558717
Breast Cancer Res. 2009;11(1):R13
19243594
J Biol Chem. 1997 May 23;272(21):13816-22
9153238
Mol Cell Endocrinol. 2008 Jul 16;289(1-2):77-84
18534741
Eur J Biochem. 1992 Sep 15;208(3):547-57
1396661
Cell Regul. 1991 May;2(5):347-55
1716464
Cancer Lett. 1999 Aug 23;143(1):15-21
10465332
J Immunol. 2007 Mar 15;178(6):3903-11
17339490
EMBO J. 2004 Jul 7;23(13):2531-43
15192707
Int J Oncol. 2008 May;32(5):1125-31
18425341
J Biol Chem. 1999 Jul 23;274(30):20805-11
10409620
Int J Cancer. 1992 Dec 2;52(6):918-23
1281143
Cancer Res. 2009 Feb 1;69(3):1117-24
19141652
J Biol Chem. 1996 May 31;271(22):13008-12
8662811
Annu Rev Cell Dev Biol. 1995;11:549-99
8689569
Cancer Res. 2008 May 15;68(10):3844-53
18483269
J Exp Zool A Comp Exp Biol. 2003 Aug 1;298(2):119-27
12884273
Mol Biol Cell. 2001 Sep;12(9):2699-710
11553709
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10159-63
1438205
Curr Opin Cell Biol. 1997 Oct;9(5):725-31
9330877
J Cell Sci. 1998 Mar;111 ( Pt 5):657-65
9454739
Int J Cancer. 2002 May 1;99(1):53-7
11948491
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8572-6
8078925
J Cell Biochem. 2009 Mar 1;106(4):714-28
19173301
Anticancer Res. 2003 Sep-Oct;23(5A):4001-6
14666709
Genome Biol. 2003;4(5):111
12734000
J Cell Biochem. 2008 May 1;104(1):82-95
17979146
Clin Exp Metastasis. 2008;25(4):305-24
17906932
Biochem Biophys Res Commun. 1994 Feb 28;199(1):93-8
8123051
Cancer Res. 1989 Dec 15;49(24 Pt 1):7064-71
2582448
J Exp Med. 1992 Jul 1;176(1):245-53
1377224
FEBS Lett. 2006 Nov 13;580(26):6069-75
17054948
Immunology. 1995 Nov;86(3):408-15
8550078
Mol Cell Biol. 1998 Nov;18(11):6719-28
9774685
Oncogene. 1999 Aug 5;18(31):4440-9
10442635
Microvasc Res. 2002 Nov;64(3):384-97
12453433
Blood. 2002 Nov 15;100(10):3741-8
12393602
EMBO J. 2002 Jul 15;21(14):3608-19
12110574
J Biol Chem. 2005 Apr 8;280(14):13205-8
15701647
J Biol Chem. 2004 Apr 16;279(16):16883-93
14963034
J Immunol. 2001 May 1;166(9):5755-62
11313419
Curr Opin Cell Biol. 1996 Apr;8(2):168-73
8791416
Blood. 1997 Dec 1;90(11):4341-53
9373245
J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80
16959960
Cell. 1991 Jan 25;64(2):327-36
1703045
J Biol Chem. 2002 Feb 22;277(8):6490-6
11741879
Cancer Res. 1997 Sep 1;57(17):3812-7
9288792
Cell Growth Differ. 1996 Sep;7(9):1187-98
8877100
Cell Adhes Commun. 1993 May;1(1):67-81
8081871
Int J Cancer. 1995 Mar 16;60(6):753-8
7896440
Int J Biochem Cell Biol. 2002 Jun;34(6):577-81
11943587
J Biol Chem. 1995 Jan 6;270(1):78-86
7814423
Int J Oncol. 2004 Oct;25(4):1157-63
15375568
Curr Med Chem. 1999 Sep;6(9):877-903
10495357
Cell Signal. 2009 Feb;21(2):253-63
19038333
Br J Cancer. 2000 Mar;82(5):1063-9
10737390
Curr Opin Hematol. 2003 Mar;10(2):150-8
12579042
Cancer Res. 2001 Mar 15;61(6):2445-52
11289113
Exp Cell Res. 1999 Apr 10;248(1):260-71
10094832
Cancer Metastasis Rev. 1994 Dec;13(3-4):411-31
7712599